You are here

Article Text

Article menu
Download PDFPDF
Letter
Anticardiolipin antibodies in patients with post-streptococcal reactive arthritis
  1. N Tamura,
  2. S Kobayashi,
  3. H Hashimoto
  1. Department of Rheumatology, Juntendo University School of Medicine, Tokyo, Japan
  1. Correspondence to:
    Dr N Tamura, Department of Rheumatology, Juntendo University School of Medicine, 2-1-1, Hongo, Bunkyo-Ku, Tokyo, 113-8421, Japan;
    tnaoto{at}med.juntendo.ac.jp

https://doi.org/10.1136/ard.61.4.374

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Group A Streptococcus is a common bacterium that induces tonsillitis, pharyngitis, and pyoderma, and, furthermore, its metabolic products cause scarlatina. It is suggested that the molecular mimicry and cross reactivity between human tissues and the micro-organism are associated with immunogenic pathogenesis of well known post-streptococcal manifestations: acute rheumatic fever and acute glomerulonephritis.1,2 Recently, non-purulent arthritis after or during streptococcal infection, HLA-B27 unrelated “post-streptococcal reactive arthritis (PSReA)”, has been reported as another manifestation associated with streptococcal infection.3–5 The pathogenesis of PSReA is unknown, but it is likely that it is an immunogenic disorder similar to acute rheumatic fever.

    Anticardiolipin antibodies (aCL) are often detected in patients with autoimmune diseases, especially systemic lupus erythematosus, …

    View Full Text